Commerzbank Aktiengesellschaft FI Makes New Investment in Royalty Pharma PLC $RPRX

Commerzbank Aktiengesellschaft FI purchased a new stake in Royalty Pharma PLC (NASDAQ:RPRX) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 21,407 shares of the biopharmaceutical company’s stock, valued at approximately $1,200,000.

A number of other hedge funds have also recently made changes to their positions in the stock. Barton Investment Management acquired a new position in Royalty Pharma in the 1st quarter valued at about $905,000. Nomura Asset Management Co. Ltd. increased its position in shares of Royalty Pharma by 16.2% in the 4th quarter. Nomura Asset Management Co. Ltd. now owns 172,418 shares of the biopharmaceutical company’s stock valued at $6,662,000 after purchasing an additional 24,048 shares during the last quarter. Qsemble Capital Management LP acquired a new stake in Royalty Pharma in the fourth quarter valued at $2,875,000. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new stake in shares of Royalty Pharma during the 4th quarter worth about $4,923,000. Finally, Thrivent Financial for Lutherans raised its holdings in Royalty Pharma by 10.4% during the fourth quarter. Thrivent Financial for Lutherans now owns 233,320 shares of the biopharmaceutical company’s stock worth $9,016,000 after purchasing an additional 22,015 shares in the last quarter. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Insider Activity

In other Royalty Pharma news, EVP Christopher Hite sold 150,000 shares of the business’s stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $54.40, for a total transaction of $8,160,000.00. Following the completion of the transaction, the executive vice president directly owned 559,399 shares of the company’s stock, valued at $30,431,305.60. The trade was a 21.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Terrance P. Coyne sold 64,399 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $53.98, for a total value of $3,476,258.02. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 362,596 shares of company stock valued at $19,992,538. 18.84% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on RPRX shares. Citigroup boosted their price objective on Royalty Pharma from $50.00 to $66.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Morgan Stanley reaffirmed an “overweight” rating and issued a $65.00 price objective on shares of Royalty Pharma in a report on Thursday, August 6th. The Goldman Sachs Group reiterated a “buy” rating and issued a $66.00 price target on shares of Royalty Pharma in a report on Thursday, August 6th. Wall Street Zen downgraded Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, Bank of America restated a “buy” rating on shares of Royalty Pharma in a research report on Wednesday, August 5th. Eight equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $60.86.

Royalty Pharma Trading Up 0.4%

Shares of RPRX opened at $59.69 on Wednesday. The stock has a market cap of $34.32 billion, a PE ratio of 41.17, a P/E/G ratio of 1.37 and a beta of 0.43. Royalty Pharma PLC has a 12 month low of $34.08 and a 12 month high of $60.44. The stock’s 50-day moving average is $56.99 and its two-hundred day moving average is $51.46. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.80 and a quick ratio of 2.80.

Royalty Pharma (NASDAQ:RPRX) last announced its earnings results on Wednesday, August 5th. The biopharmaceutical company reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.27 by $0.05. The company had revenue of $674.14 million during the quarter, compared to the consensus estimate of $758.93 million. Royalty Pharma had a return on equity of 30.01% and a net margin of 32.14%. Equities analysts forecast that Royalty Pharma PLC will post 5.3 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a dividend of $0.235 per share. The ex-dividend date is Friday, August 14th. This represents a $0.94 dividend on an annualized basis and a yield of 1.6%. Royalty Pharma’s payout ratio is currently 64.83%.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.